Biocon Limited disclosed on August 06, 2026, that B S R & Co. LLP has resigned as the statutory auditor of its material subsidiary, Biocon Biologics Limited (BBL). The resignation takes immediate effect to align BBL’s statutory auditors with those of the holding company, driven by the mandatory rotation of B S R & Co. LLP as statutory auditors of Biocon Limited under the Companies Act, 2013.

The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information was submitted to the Bombay Stock Exchange and the National Stock Exchange of India Limited, referencing SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Auditor Transition Details

B S R & Co. LLP, identified by ICAI Firm Registration Number 101248W/W-100022, was originally appointed as statutory auditor of BBL via a shareholder resolution dated July 26, 2022. Their term was scheduled to expire at the conclusion of the annual general meeting held after the financial year ended March 31, 2027.

The firm confirmed it has completed all statutory obligations up to the date of resignation. This includes issuing the audit report for the year ended March 31, 2026, dated May 07, 2026, and the limited review report for the quarter ended June 30, 2026, dated August 05, 2026.

Regulatory Compliance and Next Steps

Partner Sanjay Sharma of B S R & Co. LLP stated that the firm would file Form ADT-3 with the Registrar of Companies in due course, as required by the Companies Act, 2013. The resignation letter and Annexure A, detailing the absence of any management-imposed limitations or other material concerns, were enclosed with the exchange filing.

What the Numbers Show

The resignation reflects a standard compliance-driven transition rather than an operational dispute. By aligning the subsidiary’s auditor with the parent company’s new statutory auditor, Biocon Limited ensures consolidated audit consistency. The timely completion of the FY26 audit and Q1FY27 limited review indicates no disruption to the financial reporting timeline for the period ending June 30, 2026.

Biocon Limited shareholders approved a final dividend of ₹0.50 per equity share and adopted a comprehensive new long-term incentive plan at the company’s 48th Annual General Meeting (AGM) held on August 06, 2026. The meeting also saw the appointment of S.R. Batliboi & Associates LLP as statutory auditors for a five-year term and the reappointment of Eric Vivek Mazumdar as a director. These resolutions signal continued capital discipline and alignment of management interests with shareholder value amidst the company’s strategic consolidation of its biosimilars and generics businesses.

The Board placed nine resolutions before the members, eight of which were passed via e-voting. In addition to the dividend declaration, shareholders approved the formulation of the Biocon Unity Long Term Incentive Plan 2026, which includes performance stock units, restricted stock units, and an employee stock purchase plan. The resolution authorized financial assistance to the Biocon India Limited Employees Welfare Trust to acquire shares for implementing these equity-based incentives. The tenure of outgoing independent directors Bobby Kanubhai Parikh and Nicholas Robert Haggard concluded with the meeting, alongside the completion of the term for statutory auditors B S R & Co. LLP.

Financial Performance and Strategic Consolidation

Executive Chairperson Kiran Mazumdar-Shaw reported that operating revenues grew by 13% in FY26, while EBITDA margins expanded by nearly 200 basis points. The biosimilars segment drove this growth, delivering 16% revenue growth and a 40% increase in EBITDA on a comparable basis. A key strategic milestone was the consolidation of Biocon Biologics as a wholly owned subsidiary, integrating biosimilars, insulins, complex generics, and GLP-1 peptides under a single organizational structure.

To fund this transition and strengthen its balance sheet, Biocon raised nearly US$1 billion through two Qualified Institutions Placements (QIPs). The proceeds were utilized to consolidate full ownership of the biosimilars business, retire structured debt, and improve the company’s credit profile. Mazumdar-Shaw noted that these investments position Biocon as one of the global top five biosimilars companies by revenue and the third-largest supplier of insulins by volume.

Key Resolutions Passed

The following table summarizes the key outcomes of the 48th AGM:

Governance Updates

S.R. Batliboi & Associates LLP, Chartered Accountants (Firm Registration No. 101049W/E300004), was appointed as Statutory Auditors for a term of five consecutive years, holding office from the conclusion of the 48th AGM until the conclusion of the 53rd AGM in 2031. This appointment follows the expiration of the term of B S R & Co. LLP (Firm Registration No. 101248W/W100022). Eric Vivek Mazumdar, son of Prof. Ravi Mazumdar and nephew of Kiran Mazumdar-Shaw, was reappointed as a director liable to retire by rotation. The company confirmed that Mazumdar is not debarred from holding office by any order of SEBI or other authorities.

What the Numbers Show

The simultaneous approval of a cash dividend and a substantial equity-based incentive plan reflects a dual focus on immediate shareholder returns and long-term retention of talent critical to the company’s scientific leadership. With R&D investment maintained at 7–9% of revenues, the shift toward GLP-1 peptides and diabetes-obesity treatments suggests that future growth will be driven by high-margin specialty biologics rather than volume alone. The successful execution of a US$1 billion QIP without diluting existing shareholders significantly indicates strong institutional confidence in the post-consolidation strategy led by CEO Shreehas Tambe.